Skip to main content
ZJAMP Group Co., Ltd. logo

ZJAMP Group Co., Ltd. — Investor Relations & Filings

Ticker · 002758 ISIN · CNE100002029 LEI · 3003009OKT32LB5C0T64 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,563 across all filing types
Latest filing 2020-06-09 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002758

About ZJAMP Group Co., Ltd.

https://www.znjtgf.com

ZJAMP Group Co., Ltd. specializes in the comprehensive distribution and supply chain management of agricultural production materials. The company’s core operations encompass the procurement, storage, and sale of essential inputs, including chemical fertilizers such as urea, potash, and compound fertilizers, as well as pesticides, seeds, and agricultural machinery. Beyond product distribution, the organization provides integrated technical services, modern logistics solutions, and agricultural consultancy to enhance crop yields and farming efficiency. By leveraging an extensive network of distribution centers and service stations, the group facilitates the stable supply of high-quality agricultural resources. Its business model focuses on bridging the gap between manufacturers and end-users through efficient resource allocation and value-added services.

Recent filings

Filing Released Lang Actions
可转换公司债券2020年付息公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhejiang Huatong Pharmaceutical Co., Ltd. regarding the interest payment on its convertible bonds (华通转债) for the year 2020. It details the bond code, interest rates, payment dates, tax information, and other bond-related specifics. The document does not contain financial statements or comprehensive financial performance data but focuses on the bond interest payment event. It is a formal notice about a capital/financing activity related to bond interest payment rather than a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 4396 characters, which is sufficient for a detailed announcement but not a full report like an annual or interim report.
2020-06-09 Chinese
关于中国证监会并购重组审核委员会工作会议安排的公告
M&A Activity Classification · 95% confidence The document is an announcement from Zhejiang Huatong Pharmaceutical Co., Ltd. regarding the scheduling of a China Securities Regulatory Commission (CSRC) M&A Review Committee meeting to review the company's issuance of shares to purchase assets and related party transactions. It mentions the suspension of trading of the company's stock and convertible bonds on the meeting day to prevent abnormal price fluctuations. The document is short (761 characters) and serves as a notice about the regulatory review process and trading suspension rather than a detailed report or financial statement. It does not contain financial data or detailed analysis but is clearly related to merger and acquisition activity and regulatory review. Therefore, the document fits best under the category of M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids.
2020-06-07 Chinese
关于中国证监会并购重组审核委员会审核公司发行股份购买资产暨关联交易事项的提示性公告
M&A Activity Classification · 95% confidence The document is a short announcement (694 characters) from Zhejiang Huatong Pharmaceutical Co., Ltd. regarding the review by the China Securities Regulatory Commission's M&A Review Committee of the company's issuance of shares to purchase assets and related party transactions. It mentions the suspension and resumption of trading related to this review. The document does not contain financial statements or detailed financial data but is an update on the status of a merger and acquisition review process. It is not a full M&A filing or merger proxy statement but an announcement about the regulatory review process. Therefore, it fits best under the category 'M&A Activity' (TAR), which covers announcements and documents related to merger proposals or takeover bids. Confidence is high given the clear references to M&A review and related trading suspension.
2020-06-04 Chinese
立信会计师事务所（特殊普通合伙）关于公司《中国证监会行政许可项目审查一次反馈意见通知书》及附件的回复说明
Audit Report / Information Classification · 95% confidence The document is a detailed reply and explanation from Zhejiang Huatong Pharmaceutical Co., Ltd. regarding feedback from the China Securities Regulatory Commission (CSRC) on an administrative licensing project review. It includes extensive financial data, performance commitments, industry analysis, market competition, and the impact of COVID-19 on business operations. The document references audited financial figures, performance forecasts, and includes independent auditor and financial advisor opinions. It is a comprehensive disclosure related to a significant transaction involving asset purchase and related-party transactions, with detailed financial and operational analysis. This type of document aligns with an Audit Report / Information (AR) filing, as it contains audit opinions, accounting details, and verification of financial performance related to a regulatory review, but it is not a full Annual Report or Interim Report. It is also not a simple announcement or certification but a substantive report with financial data and audit commentary. FY 2019
2020-06-01 Chinese
海通证券股份有限公司关于公司发行股份购买资产暨关联交易之专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed independent financial advisor's special verification opinion related to a major asset restructuring involving Zhejiang Huatong Pharmaceutical Co., Ltd. It references regulatory requirements from the China Securities Regulatory Commission (CSRC), discusses compliance with laws such as the Company Law and Securities Law of China, and addresses issues like IPO commitments, control stability, business integration, financial performance, and asset evaluation. The document includes extensive financial and operational analysis, legal and accounting verification, and detailed disclosures about the transaction and its impact on the company. It is not a simple announcement but a comprehensive report with substantive financial and legal content related to a major asset purchase and related party transaction. This fits the category of an Audit Report / Information (AR), as it is a standalone audit-related report focusing on the application of accounting principles, verification of financial and legal matters, and regulatory compliance for a significant transaction, distinct from a full Annual Report or other categories. H1 2020
2020-06-01 Chinese
关于《中国证监会行政许可项目审查一次反馈意见通知书》及附件的回复说明（修订稿）
Regulatory Filings Classification · 95% confidence The document is a detailed response from Zhejiang Huatong Pharmaceutical Co., Ltd. to the China Securities Regulatory Commission (CSRC) regarding feedback on an administrative licensing project review. It includes extensive disclosures about the company's IPO commitments, control changes, business restructuring, financial performance, asset integration, risk assessments, and compliance with regulatory requirements. The content is comprehensive, covering financial data, management commitments, and legal compliance related to a significant corporate restructuring and asset acquisition. The document is lengthy (15,000 characters) and contains substantive financial and operational information, not merely an announcement or certification. It is not a typical annual report but rather a detailed regulatory filing responding to a CSRC review, including financial, legal, and operational disclosures. This fits best under Regulatory Filings (RNS), as it is a regulatory compliance document responding to a regulatory authority's feedback, containing detailed explanations and disclosures but not a formal annual report, audit report, or earnings release.
2020-06-01 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.